Tiespectus vs. AfliberceptA Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Sponsor:

EyeBiotech Ltd.

Code:

NCT07440225

Conditions

Macular Degeneration

Age-Related Macular Degeneration

Choroidal Neovascularization

Wet Macular Degeneration

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

Tiespectus

Aflibercept

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by EyeBiotech Ltd. on 2026-08-06.